U.S. Interventional Cardiology And Peripheral Industry

The U.S. interventional cardiology and peripheral market was valued at USD 7.88 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 6.0% from 2025 to 2030. This growth is primarily fueled by the increasing prevalence of cardiovascular and peripheral vascular diseases, alongside a rising preference for minimally invasive procedures among both patients and healthcare providers. Continuous innovations in device technology are also playing a crucial role in shaping market dynamics. The growing geriatric population, in combination with escalating rates of chronic conditions such as diabetes and hypertension, is significantly contributing to the rising demand for advanced interventional solutions. Moreover, favorable reimbursement frameworks are enhancing accessibility to these treatments, thereby supporting overall market expansion.

The increasing adoption of proactive healthcare practices is also influencing the market landscape. A growing number of primary care physicians and specialists are implementing early screening protocols, which has led to higher referral rates to interventional cardiologists and vascular specialists. This integration of preventive care with interventional strategies is transforming traditional treatment models. Minimally invasive procedures are increasingly being positioned as first-line therapeutic options in various clinical scenarios, reflecting a paradigm shift toward less invasive, patient-centered care. This evolving approach continues to drive growth across both coronary and peripheral intervention segments.

The demographic trend of an aging population is having a pronounced impact on the demand for interventional cardiology and peripheral procedures. According to a fact sheet released by the Population Reference Bureau in January 2024, the number of Americans aged 65 and older is projected to grow by 47% by 2050. The report also emphasizes the increasing racial and ethnic diversity among this demographic, indicating a major demographic shift by mid-century. Older adults are more likely to present with multiple comorbid conditions, making them less ideal candidates for traditional open surgical procedures. As a result, there is a growing reliance on catheter-based, minimally invasive treatments that offer effective solutions with reduced procedural risks and shorter recovery times. These technologies are particularly important for managing vascular blockages and complications while prioritizing patient comfort and quality of life.

Curious about the U.S. Interventional Cardiology And Peripheral Market, Download your FREE sample copy now and get a sneak peek into the latest insights and trends.

Innovations in interventional cardiology and peripheral vascular devices are significantly enhancing clinical outcomes and influencing treatment decisions. The latest generation of devices—including stents, balloons, and various adjunctive tools—are engineered for improved accuracy, reduced complication rates, and better long-term vessel patency. These technological improvements enable clinicians to address more complex lesions and treat a broader spectrum of patients, including those with previously untreatable conditions. Enhanced device deliverability and trackability have made it possible to navigate and treat challenging anatomical regions with greater confidence.

In line with these advancements, regulatory progress continues to support market growth. For example, in January 2024, AngioDynamics received FDA 510(k) clearance for its Auryon XL Radial Access Catheter, specifically developed for the treatment of Peripheral Arterial Disease (PAD). This catheter marks a significant innovation by offering radial access—a technique that reduces bleeding risks and shortens recovery time—as a safer and more patient-friendly alternative to the traditional femoral access route used in atherectomy procedures. The introduction of such devices not only expands treatment options but also reinforces the trend toward safer, more efficient, and patient-centric interventional solutions.

Key U.S. Interventional Cardiology And Peripheral Company Insights

Some key companies operating in the market include B. Braun SE, BD, Cardinal Health, Medtronic, Teleflex Incorporated, and W. L. Gore & Associates Inc., among others. Organizations are undertaking various strategic initiatives, such as launching new products, geographic expansions, partnerships and collaborations, and innovations, to increase their market shares. Emerging players are adopting diverse strategies, such as new product launches, to strengthen their market presence.

• Braun develops and markets medical products such as infusion therapy, pain management, clinical nutrition, dialysis, and pharmacy admixture systems, supported by divisions such as B. Braun Interventional Systems, Aesculap, and CAPS, to improve patient safety and clinical efficiency. 
• Teleflex Incorporated operates globally, providing diverse solutions in vascular and interventional access, surgical procedures, anesthesia, cardiac care, urology, emergency medicine, and respiratory care, aiming to enhance overall health and well-being.

Key U.S. Interventional Cardiology And Peripheral Companies:

• Braun SE
• BD
• Cardinal Health
• Medtronic
• Teleflex Incorporated
• L. Gore & Associates Inc.
• Cook
• Boston Scientific Corporation
• AngioDynamics
• Abbott
• OrbusNeich Medical Group Holdings Limited

Recent Developments

• In March 2025, GE HealthCare launched Flyrcado (flurpiridaz F 18) in the U.S., a first-of-its-kind PET MPI agent for coronary artery disease diagnosis, supported by Medicare pass-through payment status, aiming to enhance diagnostic accuracy and patient outcomes.
• In October 2024, Gore announced three-year data from the ASSURED Study in the U.S., demonstrating long-term safety and 100% closure success of the GORE CARDIOFORM ASD Occluder, with low adverse event rates and an 84% clinical success rate at 36 months.
• In February 2024, Biotronik launched the PK Papyrus covered coronary stent in the U.S., providing a flexible, ultrathin device for emergency treatment of acute coronary artery perforations, aiming to improve patient outcomes and reduce the need for bypass surgeries.
• In January 2024, AngioDynamics received FDA 510(k) clearance for the Auryon XL Radial Access Catheter in the U.S., expanding atherectomy options for PAD treatment, reducing access site complications, and supporting faster patient recovery with innovative laser technology.

Order a free sample PDF of the U.S. Interventional Cardiology And Peripheral Market Intelligence Study, published by Grand View Research.